2. Apoptosis Membrane Transporter/Ion Channel Metabolic Enzyme/Protease Neuronal Signaling TGF-beta/Smad Epigenetics
  3. TNF Receptor GLUT Proteasome Tau Protein PKC
  4. Punicic acid

Punicic acid  (Synonyms: Trichosanic acid)

Cat. No.: HY-139066 Purity: ≥98.0%
SDS COA Handling Instructions Technical Support

Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and ω-5 polyunsaturated fatty acids. Punicic acid has anti-inflammatory and antioxidant activities and can inhibit the expression of inflammatory mediators such as tumor necrosis factor α (TNF-α). Punicic acid can also reduce the formation of β-amyloid deposits and hyperphosphorylation of tau by increasing the expression of GLUT4 protein and inhibiting the overactivation of calpain, and is used to prevent and treat neurodegenerative diseases. In addition, punicic acid also has breast cancer inhibitor properties that depend on lipid peroxidation and PKC pathways.

For research use only. We do not sell to patients.

Punicic acid Chemical Structure

Punicic acid Chemical Structure

CAS No. : 544-72-9

Size Price Stock Quantity
Solvent
1 mg (35.92 mM * 100 μL in Methanol) In-stock
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Punicic acid Related Antibodies

Top Publications Citing Use of Products

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All GLUT Isoform Specific Products:

View All Isoforms
GLUT1 GLUT2 GLUT3 GLUT4

View All PKC Isoform Specific Products:

View All Isoforms
PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and ω-5 polyunsaturated fatty acids. Punicic acid has anti-inflammatory and antioxidant activities and can inhibit the expression of inflammatory mediators such as tumor necrosis factor α (TNF-α). Punicic acid can also reduce the formation of β-amyloid deposits and hyperphosphorylation of tau by increasing the expression of GLUT4 protein and inhibiting the overactivation of calpain, and is used to prevent and treat neurodegenerative diseases. In addition, punicic acid also has breast cancer inhibitor properties that depend on lipid peroxidation and PKC pathways[1][2][3][4].

In Vitro

Punicic acid (10 μM, 4 min) inhibits TNF-α induced neutrophil ROS overproduction without affecting fMLP or PMA (HY-18739) induced responses[2].
Punicic acid (0-40 μM, 30 min) reduces TNF-α induced p47phox phosphorylation starting from 10 mM concentration[2].
Punicic acid (10 μM, 30 min) inhibits TNF-α induced NADPH oxidase activation[2].
Punicic acid (0-40 μM; 48 h) exhibits a concentration-dependent antiproliferative effect on MDA-ERα7 and MDA-wt cells[4].
Punicic acid (40 μM; 48 h) induces apoptosis of MDA-ERα7 and MDA-wt cells and increases the percentage of cells in the G2/M phase. The ability to induce apoptosis of MDA-ERα7 and MDA-wt cells is completely blocked in the presence of 20 μM α-tocotrienol (HY-129459)[4].
Punicic acid (5-80 μM; 48 h) is partially blocked in the presence of BIM (4 μM) on MDA-ERα7 and MDA-wt cells[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Punicic acid Related Antibodies

Western Blot Analysis[1]

Cell Line: Neutrophils
Concentration: 0, 10, 20, 40 µM
Incubation Time: 30 min
Result: Reduced TNFa-induced p47phox phosphorylation starting from 10 µM concentration.
Inhibited p38MAPK phosphorylation at 20 µM similarly to p47phox inhibition of Ser345 phosphorylation, but almost no phospho-Ser345 and phosphoP38MAPK were detected.

Apoptosis Analysis[4]

Cell Line: MDA-ERα7 and MDA-wt cells
Concentration: 40 µM
Incubation Time: 48 h
Result: The apoptosis rate of BRCA cells is 86-91%.

Cell Proliferation Assay[4]

Cell Line: MDA-ERα7 and MDA-wt cells
Concentration: 0-40 µM
Incubation Time: 48 h
Result: The proliferation rate of MDA-ERα7 was only 4.5%, while that of MDA-wt was 8.5% at a dose of 40 µM.

Cell Cycle Analysis[4]

Cell Line: MDA-ERα7 and MDA-wt cells
Concentration: 40 µM
Incubation Time: 48 h
Result: The percent of MDA-ERα7 cells in the G2/M phase increased from 27.3 to 41.3% and the percent of MDA-wt cells in the G2/M phase increased from 12.3 to 20.3%.
In Vivo

Punicic acid (400 μg, i.g.; once daily for ten days) reduces significantly the TNBS-induced colonic damage in male Wistar rats by demonstrating mild inflammatory infiltration accompanied by punctate mucosal erosions[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: TNBS-induced Colitis male Wistar rat[1]
Dosage: 400 μg
Administration: i.g.
Result: Reduced the hyperactivation of neutrophils in the colon of TNBS-treated rats and inhibited the release of MPO and ROS by neutrophils, thereby reducing lipid peroxidation and tissue damage.
Molecular Weight

278.43

Formula

C18H30O2
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

CCCC/C=C\C=C\C=C/CCCCCCCC(O)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Solution, -20°C, 2 years
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (359.16 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (8.98 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (8.98 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: ≥98.0%

SDS (251 KB)

COA (237 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.5916 mL 17.9578 mL 35.9157 mL 89.7892 mL
5 mM 0.7183 mL 3.5916 mL 7.1831 mL 17.9578 mL
10 mM 0.3592 mL 1.7958 mL 3.5916 mL 8.9789 mL
15 mM 0.2394 mL 1.1972 mL 2.3944 mL 5.9859 mL
20 mM 0.1796 mL 0.8979 mL 1.7958 mL 4.4895 mL
25 mM 0.1437 mL 0.7183 mL 1.4366 mL 3.5916 mL
30 mM 0.1197 mL 0.5986 mL 1.1972 mL 2.9930 mL
40 mM 0.0898 mL 0.4489 mL 0.8979 mL 2.2447 mL
50 mM 0.0718 mL 0.3592 mL 0.7183 mL 1.7958 mL
60 mM 0.0599 mL 0.2993 mL 0.5986 mL 1.4965 mL
80 mM 0.0449 mL 0.2245 mL 0.4489 mL 1.1224 mL
100 mM 0.0359 mL 0.1796 mL 0.3592 mL 0.8979 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Punicic acid Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Punicic acid544-72-9Trichosanic acidTNF ReceptorGLUTProteasomeTau ProteinPKCTumor Necrosis Factor ReceptorTNFRGlucose transporter Protein kinase Cbioactivepomegranate seed oilisomerα-linolenic acidfatty acidchronic diseaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Punicic acid
Cat. No.:
HY-139066
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.